Hyperghrelinemia is a common feature of Prader-Willi syndrome and pituitary stalk interruption: A pathophysiological hypothesis

Hormone Research

Volumn 62, Issue 1, 2004, Pages 49-54

  Tauber, Maithé ^a,b   Auriol, Françoise Conte ^b   Moulin, Pierre ^a   Molinas, Catherine ^b   Delagnes, Véronique ^a   Salles, Jean Pierre ^a,b  

^a HÔPITAL DES ENFANTS   (France)

^b CHU PURPAN   (France)

Author keywords

Ghrelin; Growth hormone; Obesity; Pituitary stalk interruption; Prader Willi syndrome

Indexed keywords

GHRELIN; GROWTH HORMONE;

ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE DETERMINATION; HUMAN; HYPOPHYSIS TUMOR; HYPOTHALAMUS; INFUNDIBULUM; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORBID OBESITY; PATHOPHYSIOLOGY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ABNORMALITIES; AGING; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; FEMALE; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; MALE; MODELS, BIOLOGICAL; OBESITY; PEPTIDE HORMONES; PITUITARY GLAND; PRADER-WILLI SYNDROME; STEROID METABOLISM, INBORN ERRORS;

EID: 3142761626     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078862     Document Type: Article

References (19)

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-660.
2. Inui A: Ghrelin: An orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2001;2:551-560.
3. Casanueva FF, Dieguez C: Ghrelin: The link connecting growth with metabolism and energy homeostasis. Rev Endocr Metab Disord 2002;3:325-338.
4. Tschop M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature 2000;407:908-913.
5. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M: The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002;123:1120-1128.
6. Prader A, Labhart A, Willi H: Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchidismus und Oligophrenie nach myotonieartigem Zustand im Neugeborenenalter. Schweiz Med Wochenschr 1956;86:1260-1261.
7. Nicholls RD, Knepper JL: Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu Rev Genomics Hum Genet 2001;2:153-175.
8. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS: Elevated plasma ghrelin levels in Prader-Willi syndrome. Nat Med 2002;8:643-644.
9. Haqq AM, Farooqi IS, O'Rahilly S, Stadler DD, Rosenfeld RG, Pratt KL, LaFranchi SH, Purnell JQ: Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 2003;88:174-178.
10. Svendsen OL, Hassager C, Bergmann I, Christiansen C: Measurement of abdominal and intra-abdominal fat in postmenopausal women by dual energy X-ray absorptiometry anthropometry: Comparison with computerized tomography. Int J Obes Relat Metab Disord 1993;17:45-51.
11. Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Pappoti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E: Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: Comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001;86:1169-1174.
12. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF: Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: Evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995;80:942-947.
13. Cappa M, Raguso G, Palmiotto T, Faedda A, Gurreri F, Neri G, Deghenghi R, Loche S: The growth hormone response to hexarelin in patients with Prader-Willi syndrome. J Endocrinol Invest 1998;21:501-505.
14. Grugni G, Guzzaloni G, Morabito F: Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome. J Endocrinol Invest 2001;24:340-348.
15. Popovic V, Miljic D, Micic D, Damjanovic S, Arvat E, Ghigo E, Dieguez C, Casanueva FF: Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab 2003;88:3450-3453.
16. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S: A role for ghrelin in the central regulation of feeding. Nature 2001;409:194-198.
17. Seoane LM, Lopez M, Tovar S, Casanueva FF, Senaris R, Dieguez C: Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology 2003;144:544-551.
18. Cavaille J, Buiting K, Kiefmann M, Lalande M, Brannan CI, Horsthemke B, Bachellerie JP, Brosius J, Huttenhofer A: Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization. Proc Natl Acad Sci USA 2000;97:14311-14316.
19. Hewitt KN, Lee MD, Dourish CT, Clifton PG: Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 2002;71:691-700.